{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:08:46Z","timestamp":1781719726554,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00259-024-06728-4","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T04:01:35Z","timestamp":1714449695000},"page":"2367-2370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours"],"prefix":"10.1007","volume":"51","author":[{"given":"Donatienne","family":"Van Weehaeghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lapauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-6327","authenticated-orcid":false,"given":"Francesco","family":"Fraioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7956-1924","authenticated-orcid":false,"given":"Diego","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Verger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0953-7624","authenticated-orcid":false,"given":"Nathalie L","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Yakushev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Barthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Traub-Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelleke","family":"Tolboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9956-4233","authenticated-orcid":false,"given":"Elsmarieke Van De","family":"Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"6728_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO classification of Pituitary tumors. Endocr Pathol. 2022;33:6\u201326.","journal-title":"Endocr Pathol"},{"key":"6728_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","volume":"317","author":"ME Molitch","year":"2017","unstructured":"Molitch ME. Diagnosis and treatment of Pituitary adenomas: a review. JAMA. 2017;317:516\u201324.","journal-title":"JAMA"},{"key":"6728_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00330-015-3809-x","volume":"26","author":"AAJ de Rotte","year":"2016","unstructured":"de Rotte AAJ, Groenewegen A, Rutgers DR, Witkamp T, Zelissen PMJ, Meijer FJA, et al. High resolution pituitary gland MRI at 7.0 tesla: a clinical evaluation in Cushing\u2019s disease. Eur Radiol. 2016;26:271\u20137.","journal-title":"Eur Radiol"},{"key":"6728_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/j.1365-2265.2009.03723.x","volume":"72","author":"D Erickson","year":"2010","unstructured":"Erickson D, Erickson B, Watson R, Patton A, Atkinson J, Meyer F, et al. 3 Tesla magnetic resonance imaging with and without corticotropin releasing hormone stimulation for the detection of microadenomas in Cushing\u2019s syndrome. Clin Endocrinol (Oxf). 2010;72:793\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"6728_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9:847\u201375.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6728_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ecl.2020.06.002","volume":"49","author":"J MacFarlane","year":"2020","unstructured":"MacFarlane J, Bashari WA, Senanayake R, Gillett D, van der Meulen M, Powlson AS, et al. Advances in the imaging of Pituitary tumors. Endocrinol Metab Clin North Am. 2020;49:357\u201373.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"6728_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejim.2019.08.008","volume":"68","author":"P Iglesias","year":"2019","unstructured":"Iglesias P, Cardona J, D\u00edez JJ. The pituitary in nuclear medicine imaging. Eur J Intern Med. 2019;68:6\u201312.","journal-title":"Eur J Intern Med"},{"key":"6728_CR8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/cen.14425","volume":"94","author":"A Tj\u00f6rnstrand","year":"2021","unstructured":"Tj\u00f6rnstrand A, Casar-Borota O, Heurling K, Sch\u00f6ll M, Gjertsson P, Ragnarsson O, et al. Pre- and postoperative 68 Ga-DOTATOC positron emission tomography for hormone-secreting pituitary neuroendocrine tumours. Clin Endocrinol (Oxf). 2021;94:956\u201367.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"6728_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s41824-021-00104-3","volume":"5","author":"F Novruzov","year":"2021","unstructured":"Novruzov F, Aliyev A, Wan MYS, Syed R, Mehdi E, Aliyeva I, et al. The value of [68Ga]Ga-DOTA-TATE PET\/CT in diagnosis and management of suspected pituitary tumors. Eur J Hybrid Imaging. 2021;5:10.","journal-title":"Eur J Hybrid Imaging"},{"key":"6728_CR10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1053\/j.semnuclmed.2023.02.005","volume":"53","author":"D Gillett","year":"2023","unstructured":"Gillett D, MacFarlane J, Bashari W, Crawford R, Harper I, Mendichovszky IA, et al. Molecular Imaging of Pituitary tumors. Semin Nucl Med. 2023;53:530\u20138.","journal-title":"Semin Nucl Med"},{"key":"6728_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s10143-023-02077-2","volume":"46","author":"MMJ Bauman","year":"2023","unstructured":"Bauman MMJ, Graves JP, Harrison DJ, Hassett LC, Bancos I, Johnson DR, et al. The utility of PET for detecting corticotropinomas in Cushing disease: a scoping review. Neurosurg Rev. 2023;46:160.","journal-title":"Neurosurg Rev"},{"key":"6728_CR12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S2213-8587(16)30311-4","volume":"4","author":"O Koulouri","year":"2016","unstructured":"Koulouri O, Hoole AC, English P, Allinson K, Antoun N, Cheow H, et al. Localisation of an occult thyrotropinoma with 11\u00a0C-methionine PET-CT before and after somatostatin analogue therapy. Lancet Diabetes Endocrinol. 2016;4:1050.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6728_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1530\/EJE-16-0639","volume":"175","author":"O Koulouri","year":"2016","unstructured":"Koulouri O, Kandasamy N, Hoole AC, Gillett D, Heard S, Powlson AS, et al. Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11\u00a0C-methionine PET co-registered with MRI. Eur J Endocrinol. 2016;175:485\u201398.","journal-title":"Eur J Endocrinol"},{"key":"6728_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s11102-022-01230-2","volume":"25","author":"LEH Bakker","year":"2022","unstructured":"Bakker LEH, Verstegen MJT, Ghariq E, Verbist BM, Schutte PJ, Bashari WA, et al. Implementation of functional imaging using 11\u00a0C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. Pituitary. 2022;25:587\u2013601.","journal-title":"Pituitary"},{"key":"6728_CR15","doi-asserted-by":"crossref","unstructured":"Pruis IJ, Verburg FA, Balvers RK, Harteveld AA, Feelders RA, Vernooij MW et al. [ 18 F]FET PET\/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors. Journal of Nuclear Medicine. 2024;jnumed.123.266853.","DOI":"10.1530\/endoabs.90.OC3.3"},{"key":"6728_CR16","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1097\/RLU.0000000000002202","volume":"43","author":"C Heimburger","year":"2018","unstructured":"Heimburger C, Bund C, Addeo P, Goichot B, Imperiale A. 18F-FDOPA uptake reflects the efficacy of dopamine agonists treatment in Pituitary Prolactinoma. Clin Nucl Med. 2018;43:e324\u20135.","journal-title":"Clin Nucl Med"},{"key":"6728_CR17","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1097\/RLU.0000000000001721","volume":"42","author":"M Ginet","year":"2017","unstructured":"Ginet M, Cuny T, Schmitt E, Marie P-Y, Verger A. 18F-FDOPA PET imaging in Prolactinoma. Clin Nucl Med. 2017;42:e383\u20134.","journal-title":"Clin Nucl Med"},{"key":"6728_CR18","doi-asserted-by":"crossref","unstructured":"Slagboom TNA, Stenvers DJ, van de Giessen E, Roosendaal SD, de Win MML, Bot JCJ et al. Continuing challenges in the definitive diagnosis of Cushing\u2019s Disease: a structured review focusing on Molecular Imaging and a proposal for Diagnostic Work-Up. J Clin Med. 2023;12.","DOI":"10.3390\/jcm12082919"},{"key":"6728_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000095529","volume":"83","author":"C Muhr","year":"2006","unstructured":"Muhr C. Positron Emission Tomography in Acromegaly and other Pituitary Adenoma patients. Neuroendocrinology. 2006;83:205\u201310.","journal-title":"Neuroendocrinology"},{"key":"6728_CR20","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.wneu.2013.11.011","volume":"82","author":"S Rodriguez-Barcelo","year":"2014","unstructured":"Rodriguez-Barcelo S, Gutierrez-Cardo A, Dominguez-Paez M, Medina-Imbroda J, Romero-Moreno L, Arraez-Sanchez M. Clinical usefulness of Coregistered 11\u00a0C-Methionine Positron Emission Tomography\/3-T magnetic resonance imaging at the Follow-Up of Acromegaly. World Neurosurg. 2014;82:468\u201373.","journal-title":"World Neurosurg"},{"key":"6728_CR21","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.3171\/2020.3.FOCUS2052","volume":"48","author":"WA Bashari","year":"2020","unstructured":"Bashari WA, Senanayake R, Koulouri O, Gillett D, MacFarlane J, Powlson AS, et al. PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly. Neurosurg Focus. 2020;48:E8.","journal-title":"Neurosurg Focus"},{"key":"6728_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12902-020-00611-7","volume":"20","author":"M Quinn","year":"2020","unstructured":"Quinn M, Bashari W, Smith D, Gurnell M, Agha A. A remarkable case of thyrotoxicosis initially caused by graves\u2019 disease followed by a probable TSHoma - a case report. BMC Endocr Disord. 2020;20:133.","journal-title":"BMC Endocr Disord"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06728-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06728-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06728-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T06:08:00Z","timestamp":1718345280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06728-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["6728"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06728-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"30 April 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DVW received research support from General Electric and reader honoraria from Life Molecular Imaging. HB received research support from Life Molecular Imaging and Positrigo, consulting\/speaker honoraria from Hermes Medical Solutions, IBA, Lilly, Eisai and Novartis\/AAA, reader honoraria from Life Molecular Imaging, and dosing committee honoraria from Pharmtrace. MB received consulting\/speaker honoraria from Life Molecular Imaging, GE healthcare, and Roche, and reader honoraria from Life Molecular Imaging. AV received consulting\/speaker honoraria from GE healthcare, Novartis and Curium. IY received speaker honoraria from Piramal and consultant fees from ABX-CRO, Blue Earth Diagnostics, and Pentixapharm.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable to this Editorial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}